A controversial ER negative PR positive molecular subtype of breast carcinoma—Report of two cases-Reference-Cited by-同舟云学术

A controversial ER negative PR positive molecular subtype of breast carcinoma—Report of two cases

Published:2023-10-05 Issue:1 Volume:42 Page:315-318
ISSN:0888-6008
Container-title:Breast Disease
language:
Short-container-title:BD

Author:

Chandra Smita¹,Bhasin Sanya¹,Saini Sunil¹

Affiliation:

1. , Himalayan Institute of Medical Sciences, Swami Rama Himalayan University, , , , , India

Abstract

ER−/PR+ is a controversial subtype and is not formally recognised as molecular subtype of breast carcinoma. Few studies concluded that this subtype does not exist and is due to technical errors, however, in contrast others consider it to be distinct entity with different response to therapy and clinical outcome. It is also essential to know whether this subtype shows any distinct histomorphological features or prognosis. Therefore, the present two cases of controversial subtype ER−/PR+ breast cancer is being reported with both the cases showing neuroendocrinal differentiation.

Publisher

IOS Press

Subject

Cancer Research,Oncology,General Medicine

Reference10 articles.

1. Immunohistochemical surrogates for molecular classification of breast carcinoma: A 2015 update;Tang;Arch Pathol Lab Med,2016

2. Combinatorial biomarker expression in breast cancer;Rakha;Breast Cancer Res Treat,2010

3. Estrogen receptor negative/progesterone receptor positive breast cancer is not a reproducible subtype;Hefti;Breast Cancer Res,2013

4. Re-appraisal of estrogen receptor negative/progesterone receptor positive (ER-/PR+) breast cancer phenotype: True subtype or technical artefact?;Foley;Pathol Oncol Res,2018

5. ER-/PR+ breast cancer: A distinct entity, which is morphologically and molecularly close to triple negative breast cancer;Beltjens;Int J Cancer,2021